HC Wainwright Issues Optimistic Forecast for AxoGen Earnings

AxoGen, Inc. (NASDAQ:AXGN) – Investment analysts at HC Wainwright lifted their Q2 2026 earnings estimates for shares of AxoGen in a research note issued on Thursday, October 30th. HC Wainwright analyst Y. Chen now forecasts that the medical equipment provider will earn $0.03 per share for the quarter, up from their previous estimate of $0.02. HC Wainwright currently has a “Buy” rating and a $26.00 target price on the stock. The consensus estimate for AxoGen’s current full-year earnings is ($0.29) per share. HC Wainwright also issued estimates for AxoGen’s Q4 2026 earnings at $0.08 EPS and FY2026 earnings at $0.17 EPS.

AXGN has been the subject of several other research reports. Citigroup reaffirmed a “market outperform” rating on shares of AxoGen in a research report on Thursday. Jefferies Financial Group reaffirmed a “buy” rating on shares of AxoGen in a research report on Wednesday, October 29th. Citizens Jmp boosted their price objective on shares of AxoGen from $26.00 to $34.00 and gave the stock a “market outperform” rating in a research note on Thursday, October 30th. JMP Securities set a $34.00 price objective on shares of AxoGen in a research note on Thursday. Finally, Wall Street Zen upgraded shares of AxoGen from a “hold” rating to a “buy” rating in a research note on Saturday, August 9th. Eight investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $28.86.

AxoGen Price Performance

Shares of AXGN opened at $23.25 on Monday. The company has a 50 day moving average price of $17.29 and a 200-day moving average price of $14.26. AxoGen has a fifty-two week low of $9.22 and a fifty-two week high of $23.42. The stock has a market capitalization of $1.07 billion, a PE ratio of -465.00 and a beta of 1.04. The company has a debt-to-equity ratio of 0.59, a quick ratio of 2.67 and a current ratio of 4.14.

Insider Transactions at AxoGen

In other AxoGen news, Director William P. Mr. Burke sold 40,235 shares of the company’s stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $20.55, for a total transaction of $826,829.25. Following the transaction, the director owned 100 shares in the company, valued at approximately $2,055. This represents a 99.75% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In the last quarter, insiders have sold 94,004 shares of company stock worth $1,888,752. Corporate insiders own 2.78% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of AXGN. Balyasny Asset Management L.P. increased its stake in AxoGen by 183.9% during the 2nd quarter. Balyasny Asset Management L.P. now owns 1,931,158 shares of the medical equipment provider’s stock valued at $20,953,000 after purchasing an additional 1,250,968 shares in the last quarter. Wasatch Advisors LP increased its stake in AxoGen by 85.1% during the 2nd quarter. Wasatch Advisors LP now owns 1,433,782 shares of the medical equipment provider’s stock valued at $15,557,000 after purchasing an additional 659,149 shares in the last quarter. Armistice Capital LLC increased its stake in AxoGen by 106.5% during the 2nd quarter. Armistice Capital LLC now owns 1,111,319 shares of the medical equipment provider’s stock valued at $12,058,000 after purchasing an additional 573,041 shares in the last quarter. Invesco Ltd. increased its stake in AxoGen by 2,124.5% during the 1st quarter. Invesco Ltd. now owns 382,429 shares of the medical equipment provider’s stock valued at $7,075,000 after purchasing an additional 365,237 shares in the last quarter. Finally, Squarepoint Ops LLC increased its stake in AxoGen by 259.2% during the 2nd quarter. Squarepoint Ops LLC now owns 483,563 shares of the medical equipment provider’s stock valued at $5,247,000 after purchasing an additional 348,950 shares in the last quarter. Institutional investors and hedge funds own 80.29% of the company’s stock.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.